Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation against Cancer

ABSTRACT: TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation against Cancer

PROVIDER: PRJNA799733 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17712168.fastq.gz	Fastqsanger.gz
	SRR17712169_1.fastq.gz	Fastqsanger.gz
	SRR17712169_2.fastq.gz	Fastqsanger.gz
	SRR17712170_1.fastq.gz	Fastqsanger.gz
	SRR17712170_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 15

Similar Datasets

TIGIT Blockade Exerts Synergistic Effects on Microwave Ablation against Cancer

Project description:Combination immunotherapy based on immune checkpoint inhibitors (ICIs) has shown great success in the treatment of many types of cancers and has become the mainstream in the comprehensive treatment of cancers. Ablation in combination with immunotherapy has achieved tremendous efficacy in some preclinical and clinical studies. To date, our team proved that ablation in combination with ICIs was a promising antitumor therapeutic strategy for the liver metastasis of colorectal cancer (CRC). Moreover, we found that the expression of T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT) expression was up-regulated after microwave ablation (MWA), indicating that TIGIT was involved in immunosuppression, and the combination of MWA and TIGIT blockade represented a potential clinical treatment strategy. In this study, we analyzed the single-cell RNA sequencing (scRNA-seq) data from the MWA and MWA plus anti-TIGIT groups. We found that TIGIT blockade in combination with MWA significantly promoted the expansion and functions of CD8+ TILs and reshaped myeloid cells in the tumor microenvironment (TME). In conclusion, TIGIT blockade in combination with MWA was a novel treatment strategy for the liver metastasis of CRC, and this combination therapy could reprogram the TME toward an antitumor environment.

2022-03-30 | GSE194209 | GEO

TIGIT+ Tregs

Project description:TIGIT+ Tregs suppress Th1 and Th17 responses while sparing Th2 responses. Analysis of global gene expression of TIGIT+ vs. TIGIT- Tregs from naive mice reveled that TIGIT+ Tregs display an activated phenotype and are enriched for Treg signature genes including the Treg effector molecule Fgl2 which enables them to selectively spare Th2 responses. TIGIT+ and TIGIT- Tregs were sorted from naïve Foxp3-GFP KI mice (pooled spleen and lymph nodes) TIGIT: T cell immunoreceptor with Ig and ITIM domains

2014-12-12 | E-GEOD-56299 | biostudies-arrayexpress

Interfering with glycolysis potentiates the long-term effect of local tumor ablation via CD8+TCM cell differentiation [MWA+PBS or MWA+2DG]

Project description:To evaluate the genetic changes of systemic CD8+T cells induced by microwave ablation(MWA+PBS) or microwave ablation combined with 2DG(MWA+2DG),We then performed gene expression profiling analysis using data obtained from RNA-seq of 3 different spleens from two group of mice.

2024-05-04 | GSE245637 | GEO

Interfering with glycolysis potentiates the long-term effect of local tumor ablation via CD8+TCM cell differentiation [MWA or MWA+2DG group]

Project description:To evaluate the immune responses in tumor-draining lymph nodes induced by microwave ablation (MWA) or microwave ablation combined with 2DG (MWA+2DG), we then performed gene expression profiling analysis using data obtained from RNA-seq of 5 different lymph nodes from two group of mice.

2024-05-04 | GSE222600 | GEO

TIGIT inhibition and lenalidomide synergistically promote anti-myeloma immune responses after stem cell transplantation in mice

Project description:TIGIT inhibition and lenalidomide promote synergistic myeloma immunity by expanding non-exhausted memory CD8 T cells

2022-12-10 | GSE220195 | GEO

TIGIT+ Tregs

2014-12-12 | GSE56299 | GEO

The Co-inhibitory Receptor TIGIT has T cell intrinsic functions

Project description:We compared the gene expression in wild type CD4+ T cells stimulated with agonistic anti-TIGIT 4D4 antibody to that of isotype and TIGIT-deficient (KO) controls.

2011-01-01 | E-MEXP-2847 | biostudies-arrayexpress

Anti-TIGIT antibody improves PD-L1 blockade through myeloid and Treg cells

Project description:Tiragolumab, an anti-TIGIT antibody with an active IgG1κ Fc, demonstrated improved outcomes in the phase 2 CITYSCAPE trial (ClinicalTrials.gov: NCT03563716) when combined with atezolizumab (anti-PD-L1) versus atezolizumab alone. However, there remains little consensus on the mechanism(s) of response with this combination. Here we find that a high baseline of intratumoural macrophages and regulatory T cells is associated with better outcomes in patients treated with atezolizumab plus tiragolumab but not with atezolizumab alone. Serum sample analysis revealed that macrophage activation is associated with a clinical benefit in patients who received the combination treatment. In mouse tumour models, tiragolumab surrogate antibodies inflamed tumour-associated macrophages, monocytes and dendritic cells through Fcγ receptors (FcγR), in turn driving anti-tumour CD8+ T cells from an exhausted effector-like state to a more memory-like state. These results reveal a mechanism of action through which TIGIT checkpoint inhibitors can remodel immunosuppressive tumour microenvironments, and suggest that FcγR engagement is an important consideration in anti-TIGIT antibody development.

2024-03-04 | GSE260816 | GEO

The safety and efficacy of microwave ablation and radiofrequency ablation for colorectal cancer liver metastasis : A randomized controlled clinical trial

Project description:Interventions: Microwave ablation Radiofrequency ablation Primary outcome(s): The primary endpoint is the Modified RECIST evaluated by the CT scan taken after the first session of microwave ablation or radiofrequency ablation. Study Design: Parallel Randomized

| 2651257 | ecrin-mdr-crc

Systemically administered HMGN1 immunostimulatory peptide with anti-PD-L1 antibody exerts synergistic antitumor effects

Project description:Systemically administered HMGN1 immunostimulatory peptide with anti-PD-L1 antibody exerts synergistic antitumor effects

| PRJNA579156 | ENA